Calmodulin kinase II inhibition protects against structural heart disease

Rong Zhang, Michelle S C Khoo, Yuejin Wu, Yingbo Yang, Chad E. Grueter, Gemin Ni, Edward E. Price, William Thiel, Silvia Guatimosim, Long Sheng Song, Ernest C. Madu, Anisha N. Shah, Tatiana A. Vishnivetskaya, James B. Atkinson, Vsevolod V. Gurevich, Guy Salama, W. J. Lederer, Roger J. Colbran, Mark E. Anderson

Research output: Contribution to journalArticle

410 Citations (Scopus)

Abstract

β-Adrenergic receptor (βAR) stimulation increases cytosolic Ca2+ to physiologically augment cardiac contraction, whereas excessive βAR activation causes adverse cardiac remodeling, including myocardial hypertrophy, dilation and dysfunction, in individuals with myocardial infarction. The Ca2+-calmodulin-dependent protein kinase II (CaMKII) is a recently identified downstream element of the βAR-initiated signaling cascade that is linked to pathological myocardial remodeling and to regulation of key proteins involved in cardiac excitation-contraction coupling. We developed a genetic mouse model of cardiac CaMKII inhibition to test the role of CaMKII in βAR signaling in vivo. Here we show CaMKII inhibition substantially prevented maladaptive remodeling from excessive βAR stimulation and myocardial infarction, and induced balanced changes in excitation-contraction coupling that preserved baseline and βAR-stimulated physiological increases in cardiac function. These findings mark CaMKII as a determinant of clinically important heart disease phenotypes, and suggest CaMKII inhibition can be a highly selective approach for targeting adverse myocardial remodeling linked to βAR signaling.

Original languageEnglish (US)
Pages (from-to)409-417
Number of pages9
JournalNature Medicine
Volume11
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Calcium-Calmodulin-Dependent Protein Kinases
Calcium-Calmodulin-Dependent Protein Kinase Type 2
Adrenergic Receptors
Heart Diseases
Excitation Contraction Coupling
Myocardial Infarction
Genetic Models
Hypertrophy
Dilatation
Chemical activation
Phenotype

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Zhang, R., Khoo, M. S. C., Wu, Y., Yang, Y., Grueter, C. E., Ni, G., ... Anderson, M. E. (2005). Calmodulin kinase II inhibition protects against structural heart disease. Nature Medicine, 11(4), 409-417. https://doi.org/10.1038/nm1215

Calmodulin kinase II inhibition protects against structural heart disease. / Zhang, Rong; Khoo, Michelle S C; Wu, Yuejin; Yang, Yingbo; Grueter, Chad E.; Ni, Gemin; Price, Edward E.; Thiel, William; Guatimosim, Silvia; Song, Long Sheng; Madu, Ernest C.; Shah, Anisha N.; Vishnivetskaya, Tatiana A.; Atkinson, James B.; Gurevich, Vsevolod V.; Salama, Guy; Lederer, W. J.; Colbran, Roger J.; Anderson, Mark E.

In: Nature Medicine, Vol. 11, No. 4, 04.2005, p. 409-417.

Research output: Contribution to journalArticle

Zhang, R, Khoo, MSC, Wu, Y, Yang, Y, Grueter, CE, Ni, G, Price, EE, Thiel, W, Guatimosim, S, Song, LS, Madu, EC, Shah, AN, Vishnivetskaya, TA, Atkinson, JB, Gurevich, VV, Salama, G, Lederer, WJ, Colbran, RJ & Anderson, ME 2005, 'Calmodulin kinase II inhibition protects against structural heart disease', Nature Medicine, vol. 11, no. 4, pp. 409-417. https://doi.org/10.1038/nm1215
Zhang, Rong ; Khoo, Michelle S C ; Wu, Yuejin ; Yang, Yingbo ; Grueter, Chad E. ; Ni, Gemin ; Price, Edward E. ; Thiel, William ; Guatimosim, Silvia ; Song, Long Sheng ; Madu, Ernest C. ; Shah, Anisha N. ; Vishnivetskaya, Tatiana A. ; Atkinson, James B. ; Gurevich, Vsevolod V. ; Salama, Guy ; Lederer, W. J. ; Colbran, Roger J. ; Anderson, Mark E. / Calmodulin kinase II inhibition protects against structural heart disease. In: Nature Medicine. 2005 ; Vol. 11, No. 4. pp. 409-417.
@article{eb6279152cd843618411bc402b51f6de,
title = "Calmodulin kinase II inhibition protects against structural heart disease",
abstract = "β-Adrenergic receptor (βAR) stimulation increases cytosolic Ca2+ to physiologically augment cardiac contraction, whereas excessive βAR activation causes adverse cardiac remodeling, including myocardial hypertrophy, dilation and dysfunction, in individuals with myocardial infarction. The Ca2+-calmodulin-dependent protein kinase II (CaMKII) is a recently identified downstream element of the βAR-initiated signaling cascade that is linked to pathological myocardial remodeling and to regulation of key proteins involved in cardiac excitation-contraction coupling. We developed a genetic mouse model of cardiac CaMKII inhibition to test the role of CaMKII in βAR signaling in vivo. Here we show CaMKII inhibition substantially prevented maladaptive remodeling from excessive βAR stimulation and myocardial infarction, and induced balanced changes in excitation-contraction coupling that preserved baseline and βAR-stimulated physiological increases in cardiac function. These findings mark CaMKII as a determinant of clinically important heart disease phenotypes, and suggest CaMKII inhibition can be a highly selective approach for targeting adverse myocardial remodeling linked to βAR signaling.",
author = "Rong Zhang and Khoo, {Michelle S C} and Yuejin Wu and Yingbo Yang and Grueter, {Chad E.} and Gemin Ni and Price, {Edward E.} and William Thiel and Silvia Guatimosim and Song, {Long Sheng} and Madu, {Ernest C.} and Shah, {Anisha N.} and Vishnivetskaya, {Tatiana A.} and Atkinson, {James B.} and Gurevich, {Vsevolod V.} and Guy Salama and Lederer, {W. J.} and Colbran, {Roger J.} and Anderson, {Mark E.}",
year = "2005",
month = "4",
doi = "10.1038/nm1215",
language = "English (US)",
volume = "11",
pages = "409--417",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Calmodulin kinase II inhibition protects against structural heart disease

AU - Zhang, Rong

AU - Khoo, Michelle S C

AU - Wu, Yuejin

AU - Yang, Yingbo

AU - Grueter, Chad E.

AU - Ni, Gemin

AU - Price, Edward E.

AU - Thiel, William

AU - Guatimosim, Silvia

AU - Song, Long Sheng

AU - Madu, Ernest C.

AU - Shah, Anisha N.

AU - Vishnivetskaya, Tatiana A.

AU - Atkinson, James B.

AU - Gurevich, Vsevolod V.

AU - Salama, Guy

AU - Lederer, W. J.

AU - Colbran, Roger J.

AU - Anderson, Mark E.

PY - 2005/4

Y1 - 2005/4

N2 - β-Adrenergic receptor (βAR) stimulation increases cytosolic Ca2+ to physiologically augment cardiac contraction, whereas excessive βAR activation causes adverse cardiac remodeling, including myocardial hypertrophy, dilation and dysfunction, in individuals with myocardial infarction. The Ca2+-calmodulin-dependent protein kinase II (CaMKII) is a recently identified downstream element of the βAR-initiated signaling cascade that is linked to pathological myocardial remodeling and to regulation of key proteins involved in cardiac excitation-contraction coupling. We developed a genetic mouse model of cardiac CaMKII inhibition to test the role of CaMKII in βAR signaling in vivo. Here we show CaMKII inhibition substantially prevented maladaptive remodeling from excessive βAR stimulation and myocardial infarction, and induced balanced changes in excitation-contraction coupling that preserved baseline and βAR-stimulated physiological increases in cardiac function. These findings mark CaMKII as a determinant of clinically important heart disease phenotypes, and suggest CaMKII inhibition can be a highly selective approach for targeting adverse myocardial remodeling linked to βAR signaling.

AB - β-Adrenergic receptor (βAR) stimulation increases cytosolic Ca2+ to physiologically augment cardiac contraction, whereas excessive βAR activation causes adverse cardiac remodeling, including myocardial hypertrophy, dilation and dysfunction, in individuals with myocardial infarction. The Ca2+-calmodulin-dependent protein kinase II (CaMKII) is a recently identified downstream element of the βAR-initiated signaling cascade that is linked to pathological myocardial remodeling and to regulation of key proteins involved in cardiac excitation-contraction coupling. We developed a genetic mouse model of cardiac CaMKII inhibition to test the role of CaMKII in βAR signaling in vivo. Here we show CaMKII inhibition substantially prevented maladaptive remodeling from excessive βAR stimulation and myocardial infarction, and induced balanced changes in excitation-contraction coupling that preserved baseline and βAR-stimulated physiological increases in cardiac function. These findings mark CaMKII as a determinant of clinically important heart disease phenotypes, and suggest CaMKII inhibition can be a highly selective approach for targeting adverse myocardial remodeling linked to βAR signaling.

UR - http://www.scopus.com/inward/record.url?scp=20244362095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244362095&partnerID=8YFLogxK

U2 - 10.1038/nm1215

DO - 10.1038/nm1215

M3 - Article

VL - 11

SP - 409

EP - 417

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 4

ER -